MedTrace Logo

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

NCT02966353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2020-04-30

Study results available
· View outcomes & findings →

Summary

This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria for dose hold or dose reduction

Conditions

  • Primary Myelofibrosis
  • Post-Polycythemia Vera-Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis

Interventions

DRUG

ruxolitinib

Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2018-07-24
Completion
2019-02-15

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Canada
  • Germany
  • Greece
  • Italy
  • Japan
  • Russia
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02966353 on ClinicalTrials.gov